Targeting AS Damage

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18 F-fluoride positron emission tomography

<p>Whether TNF inhibitors prevent structural damage in ankylosing spondylitis remains a controversial…

The RAPID-axSpA study of ankylosing spondylitis…

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial Spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.

Anti-IL17 Benefits Persist in Spine Disease

Rapid responses seen for secukinumab in ankylosing spondylitis

No Comments Yet.

Leave a comment